| Literature DB >> 33153599 |
Tianrun Xu1, Chunxiu Hu1, Qiuhui Xuan1, Guowang Xu2.
Abstract
Lipids are vital biological molecules and play multiple roles in cellular function ofEntities:
Keywords: Biomarker discovery; High-resolution mass spectrometry; Liquid chromatography; Pseudotargeted lipidomics; Targeted lipidomics; Untargeted lipidomics
Mesh:
Substances:
Year: 2020 PMID: 33153599 PMCID: PMC7525665 DOI: 10.1016/j.aca.2020.09.060
Source DB: PubMed Journal: Anal Chim Acta ISSN: 0003-2670 Impact factor: 6.558
Fig. 1Basic structural information of eight lipid categories classified by Fahy et al. [3].
Fig. 2The illustration of the diversity and complexity of lipid structures by taking GPs and SPs as examples. GPs structure diversity lies in the variety of head group, fatty acyl chains at the sn-1 and sn-2 positions as well as the linkage between glycerol backbone and sn-1 fatty acids. The head group generally represents phosphate group, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylinositol and phosphatidylserine, which respectively defines the classes of GPs as PA, PC, PE, PG, PI and PS, etc. Another aspect of diversity stems from three different linkage: ester (acyl-), ether (alkyl-) and vinyl-ether (alkenyl-). Besides, the fatty acyl chains also vary in chain length, level of unsaturation, double bond location and cis-trans geometries. Similarly, combinations of different structures of head group, sphingoid based type and N-acyl chain constitute tens of thousands of SPs.
Fig. 3Annotation hierarchy of PC (P-16:1(9Z)/18:0) by high resolution mass spectrometry and ion mobility spectroscopy (HRAM: high resolution and accurate mass; UHRAMS: ultrahigh resolution and accurate mass spectrometry). Reproduced with permission from literature [12].
Fig. 4A workflow of MS-based analytical strategies for untargeted, targeted and pseudotargeted lipidomics.
Representative applications of disease biomarkers for prediction, diagnosis and prognosis.
| (1) Prediction | |||||||
|---|---|---|---|---|---|---|---|
| Category | Disease | Sample | Analytical strategy | Analytical platform | Up-regulated lipids | Down-regulated lipids | Ref. |
| Metabolic syndrome | Type 2 diabetes (T2D) | Plasma | Targeted | UHPLC-MS/MS, shotgun | Cer (d18:0) | – | [ |
| Serum | Targeted | HPLC-MS/MS | LPI 16:1, PC 34:3, TAG 50:2(16:2), | PE (18:0p/20:4) | [ | ||
| Serum | Targeted | GC-MS/MS | – | linoleic acid | [ | ||
| Cardiovascular disease (CVD) | Plasma | Targeted | UHPLC-MS/MS | Cer(d18:1) | – | [ | |
| Cancer | Prostate | Serum | Untargeted | UHPLC-MS/MS, GC-MS | – | GPs, choline, FFAs | [ |
| Colorectal | Serum | Targeted | HPLC-MS/MS | PC (30:0) | LPC (18:0) | [ | |
| Breast | Serum | Targeted | HPLC-MS/MS | PC (30:0) | LPC (18:0) | [ | |
| (2) Diagnosis and classification | |||||||
| Metabolic syndrome | T2D | Serum | Pseudo-targeted | UHPLC-MS/MS | TGs, DGs, PEs, LPEs | HexCers, PE-Os, PC-Os, LPC-Os | [ |
| Nonalcoholic fatty liver disease (NAFLD) | Tissue, plasma, urine | Targeted | LC-MS/MS, GC-MS | SPs | GPs | [ | |
| Neurological disorder | Alzheimer’s disease (AD) | Plasma | Untargeted | UHPLC-MS/MS | – | CEs | [ |
| Tissue, serum | Targeted | HPLC-MS/MS | SMs | – | [ | ||
| Cancer | Breast | Tissue | Untargeted | UHPLC-MS | PCs, PEs, PIs, SM, Cer | TAGs | [ |
| Kidney | Plasma | Untargeted | UHPLC-MS/MS | Saturated C12–C16 FFAs, TAGs | – | [ | |
| Hepatocellular carcinoma (HCC) | Tissue, cell | Untargeted | HPLC-MS/MS | – | C16:0-containing GPs | [ | |
| Prostate | Tissue | Untargeted | UHPLC-MS/MS | CEs | – | [ | |
| Non-small cell lung cancer (NSCLC) | Tissue | Targeted | Shotgun | PI (38:2), PI (38:3), | SM (40:1), SM (42:1), SM (36:1) | [ | |
| Viral disease | Lassa | Serum | Untargeted | HPLC-MS | – | PAFs | [ |
| (3) Prognosis evaluation | |||||||
| Metabolic syndrome | CVD | Plasma, serum | Targeted | UHPLC-MS/MS | Cer, PCs | – | [ |
| Neurological disorder | Stroke | Plasma | Untargeted | LC-MS | – | LPC (20:4) | [ |
| Cancer | Breast | Tissue | Untargeted | UHPLC-MS/MS | PC(30:0), PC (32:0), PC (32:1), PC (32:2) | – | [ |
| Kidney | Serum | Untargeted | Shotgun | MAG (16:0) | DAG (32:0), DAG (36:0) | [ | |
| Prostate | Plasma | Untargeted | LC-MS/MS | Cer(d18:1/24:1), SM(d18:2/16:0), PC(16:0/16:0) | – | [ | |
| Ovarian | Plasma | Untargeted | UHPLC-MS | – | LPG(20:5) | [ | |
| Viral disease | Ebola virus disease (EVD) | Plasma | Untargeted | UHPLC-MS/MS | PG(18:1/22:6) | PI(18:0/20:4), Cer(d18:0/24:0), LPC(20:0) | [ |